UC San Diego Health
Management of postop ptosis depends on severity
Prediction model shows potential for identifying cancer survivors at risk for opioid misuse
Dual target CAR T/natural killer cell therapy shows promise for B-cell malignancies
ORLANDO — Two major impediments to widespread adoption of chimeric antigen receptor T-cell therapies are their cost and antigen loss that makes them less effective over time. An allogeneic approach that combines CARs and natural killer cells into one therapy may be the solution, according to preclinical research presented at ASH Annual Meeting and Exposition.
Oxervate heals corneal lesions in neurotrophic keratopathy
Hematologists, oncologists elected to National Academy of Medicine
Antineoplastic therapy ordering protocol allows APPs to ‘expand their scope of practice’
Pembrolizumab fails to improve outcomes in multiple myeloma
Vaping, cigarette smoking worsen sleep quality in women
Driving Killer CARs into Cancer
Automobile pioneer Henry Ford once said of his best-selling Model T, “Any customer can have a car painted any color that he wants so long as its black.” Ford did not mean that all his Model Ts would be one color, but that by selling one model with few customizations on a massive scale, it would bring down the price of each unit to make them more affordable.